Total Number of Communication Reports: 0
Monthly communication reports in the last 6 months: 0
Subject matters | Details | Categories |
---|---|---|
Health
|
Bill C-64: An Act respecting pharmacare, with a particular focus on access to medicines and rare disease and orphan drug policies.
|
Policies or Program, Legislative Proposal, Bill or Resolution
|
Health
|
Engagement with officials on issues related to the National Strategy for Rare Disease Drugs, and other policies or programs related to rare diseases.
|
Policies or Program
|
Health
|
Federally-funded public drug plans, with respect to reimbursement for drug products for federal plan beneficiaries.
|
Policies or Program
|
Budget, Health
|
Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals including addressing any health technology assessment-related or other policy discussions that might involve Health Canada and its ongoing relationship with Canada's Drug Agency and/or other pan-Canadian health organizations.
|
Policies or Program
|
Health, Industry, Intellectual Property
|
Guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board.
|
Policies or Program
|
Health, Industry
|
Innovation, Science and Economic Development Canada regarding the Innovation and Skills Agenda and other government policies and programs related to incentivizing research and development activities in Canada, including the Biomanufacturing and Life Sciences Strategy.
|
Policies or Program
|
Health
|
Regulatory amendments and/or guidelines and/or policies related to the Food and Drugs Act and Health Canada review of drugs for rare diseases.
|
Policies or Program, Regulation
|
Address:
3100 Rutherford Road Suite 300
Vaughan, ON L4K 0G6
Canada
Telephone number:
866-393-1188
Web address:
https://alexion.com/worldwide/canada
Kathleen Whelan, Country Lead, International Government Affairs & Policy
Alexion Pharma Canada Corp. is not a coalition.
The activities of Alexion Pharma Canada Corp. are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
Alexion Pharma Canada Corp. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Chris Gray | Public offices held
Firm: 3Sixty Public Affairs Inc.